The reduced DAXX and ATRX expression in more malignant cases was consistent with findings in human oncology, particularly the study from Segersten et al., who reported that a loss of DAXX expression was significantly associated with a higher tumour stage (T2–4 compared to Ta and T1) in human urothelial bladder carcinomas [24]. The gene discussed is DAXX; the disease is neoplasm.